Medical therapy for ulcerative colitis: The state of the art and beyond

Current Gastroenterology Reports

Volumn 6, Issue 6, 2004, Pages 488-495

  Ross, Andrew S ^a   Cohen, Russell D ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BALSALAZIDE; BETA1A INTERFERON; BIOLOGICAL PRODUCT; BUDESONIDE; BUTYRIC ACID; CORTICOSTEROID; CYCLOSPORIN; ENOXAPARIN; EPIDERMAL GROWTH FACTOR; HEPARIN; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; OLSALAZINE; PEGINTERFERON ALPHA2B; PRASTERONE; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; REPIFERMIN; SALAZOSULFAPYRIDINE; TINZAPARIN; TRICHURIS SUIS EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

APHERESIS; BIOLOGICAL THERAPY; CHILL; CLINICAL TRIAL; COLON RESECTION; CROHN DISEASE; DISEASE EXACERBATION; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; HUMAN; HYPERTENSION; LEUKEMIA; LEUKOPENIA; LONG TERM CARE; LOW DRUG DOSE; LYMPHOMA; MAINTENANCE THERAPY; META ANALYSIS; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PANCREATITIS; PROPHYLAXIS; REMISSION; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; TREATMENT FAILURE; ULCERATIVE COLITIS;

EID: 9944255147     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-004-0071-9     Document Type: Review

References (54)

1. Hanauer SB, Present DH: The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Dis 2003, 3:81-92.
2. Sutherland L, MacDonald JK: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003 (3):CDO00543.
3. Kane SV, Bjorkman DJ: The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord 2003, 3:210-218.
4. Green JR, Lobo AJ, Holdsworth CD, et al.: Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998, 114:15-22.
5. Levine DS, Riff DS, Pruitt R, et al.: A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002, 97:1398-1407.
6. Pruitt R, Hanson J, Safdi M, et al.: Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002, 97:3078-3086.
7. Cohen RD: Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep 2002, 4:497-505.
8. Guijarro L, Mate J, Gonzalez-Lara V, et al.: Supplemental N-acetyl-L-cysteine improves the efficacy of mesalazine in the treatment of mild to moderate ulcerative colitis. Randomized, placebo-controlled, pilot study. Gastroenterology 2004, 126(Suppl 2):A464.
9. Lindgren S, Lofberg R, Bergholm L, et al.: Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand J Gastroenterol 2002, 37 705-710.
10. Bar-Meir S, Fidder HH, Faszczyk M, et al.: Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis. Dis Colon Rectum 2003, 46:929-936.
11. Gross V, Bar-Meir S, Lavy A, et al.: Budesonide foam vs. budesonide enema in acute ulcerative proctosigmoiditis. Gastroenterology 2004, 126(Suppl 2):A-465.
12. Andus T, Klebl F, Rogler G, et al.: Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther 2003, 17:409-414.
13. Ardizzone S, Molteni P, Imbesi V, et al.: Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997, 25:330-333.
14. Sood A, Midha V, Sood N, Avasthi G: Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol 2003, 22(3):79-81.
15. Fraser AG, Orchard TR, Jewell DP: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002, 50:485-489.
16. Lobel EZ, Korelitz BI, Xuereb MA, Panagopoulous G: A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol 2004, 99:462-465.
17. Warman JI, Korelitz BI, Fleisher MR, Janardhanam R: Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003, 37:220-225.
18. Mahadevan U, Loftus EV Jr, Tremaine WJ, et al.: Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002, 8:311-316.
19. Martinez F, Nos P, Pastor M, et al.: Adverse effects of azathioprine in the treatment of inflammatory bowel disease. Revista Espanola de Enfermedades Digestivas 2001, 93:769-778.
20. Cohen RD: Intravenous cyclosporine in severe ulcerative colitis: ready to stand alone? Gastroenterology 2001, 120 1541-1543.
21. Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841-1845.
22. Van Assche G, D'Haens G, Noman M, et al.: Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003, 125:1025-1031.
23. Arts J, D'Haens G, Zeegers M, et al.: Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004, 10:73-78.
24. Rayner CK, McCormack G, Emmanuel AV, Kamm MA: Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003, 18:303-308.
25. Probert CS, Hearing SD, Schreiber S, et al.: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003, 52 998-1002.
26. Actis GC, Bruno M, Pinna-Pintor M, et al.: Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002, 34:631-634.
27. Kohn A, Prantera C, Pera A, et al.: Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 2002, 34:626-630.
28. Armuzzi A, Lupascu A, Fedili P, et al.: Infliximab in the treatment of moderate to severe glucocorticoid dependent ulcerative colitis: a randomized methylprednisolone controlled trial. Gastroenterology 2004, 126(Suppl 2):A-464.
29. Nikolaus S, Rutgeerts P, Fedorak R, et al.: Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 2003, 52:1286-1290.
30. Tilg H, Vogelsang H, Ludwiczek O, et al.: A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003, 52:1728-1733.
31. Kruis W, Bar-Meir S, Feher J, et al.: The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003, 1:36-43.
32. Rembacken BJ, Snelling AM, Hawkey PM, et al.: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999, 354 635-639.
33. Gionchetti P, Rizzello F, Venturi A, et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
34. Mimura T, Rizzello F, Helwig U, et al.: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108-114.
35. Gosselink MP, Schouten WR, van Lieshout LM, et al.: Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004, 47 876-884
36. Plevy S, Salzberg B, Van Assche G, et al.: A humanized anti-CD3 monoclonal antibody, visulizumab, for treatment of severe steroid-refractory ulcerative colitis: results of a phase I study. Gastroenterology 2004, 126(Suppl 2):A-75.
37. Bentwich Z, Weisman Z, Moroz C, et al.: Immune dysregulation in Ethiopian immigrants in Israel: relevance to helminth infections? Clin Exp Immunol 1996, 103:239-243.
38. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ: Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni. J Infect Dis 1996, 173:269-272.
39. Summers RW, Elliott DE, Qadir K, et al.: Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 2003, 98 2034-2041.
40. Vernia P, Annese V, Bresci G, et al.: Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest 2003, 33:244-248.
41. Sinha A, Nightingale J, West KP, et al.: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003, 349 350-357.
42. Farrell RJ: Epidermal growth factor for ulcerative colitis. N Engl J Med 2003, 349:395-397.
43. Hanauer S, Miner P, Keshavarzian A, et al.: Randomized, double-blind, placebo-controlled, parallel arm, safety and efficacy trial of once-daily, oral OPC-6535 in the treatment of active ulcerative colitis. Gastroenterology 2004, 126(Suppl 2) A-112.
44. Ang YS, Mahmud N, White B, et al.: Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther 2000, 14:1015-1022.
45. Panes J, Esteve M, Cabre E, et al.: Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology 2000, 119:903-908.
46. Dotan I, Hallak A, Arber N, et al.: Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci 2001, 46:2239-2244.
47. Bloom S, Kiilerich S, Lassen MR, et al.: Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther 2004, 19:871-878.
48. Sandborn WJ, Sands BE, Wolf DC, et al.: Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 2003, 17:1355-1364.
49. Kruis W, Morgenstern J, Loefberg R, et al.: Successful apheresis therapy in steroid-refractory ulcerative colitis. Gastroenterology 2004, 126(Suppl 2):A-628.
50. Domenech E, Hinojosa J, Esteve M, et al.: Prospective, open, pilot study of granulocytapheresis for the treatment of steroid-dependent inflammatory bowel disease: preliminary results. Gastroenterology 2004, 126(Suppl 2):A-630.
51. Okada H, Kato J, Hori SI, et al.: Centrifugal leukocytapheresis therapy without concurrent corticosteroid administration for ulcerative colitis. Gastroenterology 2004, 126(Suppl 2):A-632.
52. Suzuki Y, Yoshimura N, Saniabadi A, Saito Y: A prospective study of selective neutrophil and monocyte adsorptive apheresis as a first line treatment for steroid naive patients with active ulcerative colitis: a step toward steroid free treatment of ulcerative colitis. Gastroenterology 2004, 126(Suppl 2):A-467.
53. Sawada K, Hiwatashi N, Munakata A, et al.: A multicenter randomized controlled study of safety and efficacy of adsorptive granulocyte and monocyte apheresis in patients with active ulcerative colitis. Gastroenterology 2004, 126(Suppl 2):A-462.
54. Hanai H, Iida T, Takeuchi K, et al.: Adsorptive granulocyte and monocyte/macrophage apheresis versus prednisolone in patients with corticosteroid dependent ulcerative colitis. Gastroenterology 2004, 126(Suppl 2):A-206.